To view this email as a web page, click here.
May 13, 2019
 
Ongoing study evaluates sirolimus as therapeutic option for uveitis
image description here An ongoing phase III, sham-controlled study is investigating intravitreal sirolimus 440 μg (Opsiria, Santen) for the treatment of active, non-infectious uveitis of the posterior segment, said Steven Yeh, MD.
Continue
ADVERTISEMENT
 
Tocilizumab effective for managing posterior segment inflammation
image description here The STOP-Uveitis Study has shown that intravenous infusions of the humanized monoclonal antibody tocilizumab are effective as a novel therapeutic management approach for non-infectious uveitis.
Find out
ADVERTISEMENT
 
RELATED ARTICLES
 
IL-6 inhibition shows promise as treatment for non-infectious uveitis
Real-world study of the fluocinolone acetonide implant show its benefits for treating DME
Diabetic eye disease: Best treatment options for your patients
Targeting angiopoietin-2 + VEGF-A to treat DME
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.